Platelet-rich plasma (PRP) · Lesson 24 of 25 · 2 min

What is next for PRP? Exosomes, AI and standardization

PRP research is moving toward standardized preparation, PRP-derived exosomes and AI-based prediction. All of it is still under study.

Gloved hands placing a sample tube into a centrifuge

Key takeaways.

  • Inconsistent preparation is described as the main obstacle to clear evidence on PRP.
  • The 2025 GRIIP consensus issued 23 recommendations, a step toward standardization.
  • PRP-derived exosomes are being studied in wound healing, nerve repair and orthopedics.
  • Exosome therapies are not FDA-approved for therapeutic use.
  • AI is being explored for predicting individual response and refining dose.
  • Dozens of registered clinical trials are examining dose, new uses and mechanisms.

Standardization comes first

The main obstacle in PRP research is heterogeneity. Preparations, supplies and training differ between clinics and studies, so results are hard to combine. Systematic reviews have called for consistent preparation protocols and standardized reporting.

The 2025 consensus from the International Research Group on Platelet Injections (GRIIP) set out 23 recommendations on contraindications. A scoring system called WESS-PQR has also been proposed for reporting. PRP applications are considered off-label.

PRP-derived exosomes

Exosomes are extracellular vesicles, which are tiny membrane-bound particles that cells release and that carry bioactive cargo. PRP-derived exosomes are a newer research area. Studies from 2024 and 2025 have examined them in diabetic wound healing, nerve regeneration and orthopedic uses with scaffolds.

This work is early. Exosome therapies are not FDA-approved for therapeutic use.

Artificial intelligence

A 2024 scoping review examined AI in regenerative orthopedics, including PRP. The uses under study include identifying prognostic factors and predicting which individuals are likely to respond.

Other proposed uses are dose optimization from large outcome datasets and better clinical trial design. These tools are in development and are not yet routine.

Ongoing trials

As of 2025, dozens of PRP trials were registered on ClinicalTrials.gov. They examine dose, new applications and mechanisms.

One example is a UCSF study (NCT06451120) enrolling about 60 people in two age groups. It aims to identify protein changes after repeated knee PRP injections.

Educational content for healthcare professionals. Not a treatment recommendation. PRP applications are considered off-label.

Platelet-rich plasma (PRP): 0 of 25 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • How current trials may change practice
  • PRP-derived exosomes in more depth
  • Standardized reporting of PRP preparations
  • Emerging applications under investigation

Common questions.

What are PRP-derived exosomes?
They are extracellular vesicles derived from platelet-rich plasma that carry bioactive cargo. They are being studied in wound healing, nerve repair and orthopedics, and exosome therapies are not FDA-approved for therapeutic use.
Why is PRP standardization important?
Without consistent preparation and reporting, studies cannot be compared reliably. Reviews identify this heterogeneity as the main obstacle to clear evidence.
How might AI be used in PRP therapy?
Research is exploring AI for identifying prognostic factors, predicting individual response, optimizing dose and improving trial design. These uses are still in development.

Sources

  • UCSF Clinical Trials. Platelet Rich Plasma Injections In Young And Old Human Subjects With Knee Osteoarthritis. ClinicalTrials.gov Identifier: NCT06451120. 2024.
  • Smith J, et al. Systematic review of platelet-rich plasma in medical and surgical specialties: quality, evaluation, evidence, and enforcement. Plast Reconstr Surg. 2024;154(2):402e-414e.
  • Gupta M, et al. Therapeutic potential of extracellular vesicles (exosomes) derived from platelet-rich plasma: a literature review. J Cosmet Dermatol. 2025;24(3):891-904.

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.